Regarding ADA and IFX, EULAR guidelines for the treatment of BD domains propose their use in patients with insufficient responses to conventional IS or in case of severe involvement that may lead to vision loss, but there is no recommendation with other anti-TNF-alpha drugs [39]. Here, TNF is linked to Behcet disease.